RxDoctor Payments Data

Gregory Spencer, MD

Ophthalmology · Oxnard, CANPI 1821127770

Payments from drug & device makers

$679in general payments, 2019–2025

Across 29 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$214
  • Ocular Therapeutix, Inc.$104
  • Glaukos Corporation$93
  • Alcon$92
  • Oyster Point Pharma, Inc.$54
  • Kala Pharmaceuticals, Inc.$38
  • plus $83 from 4 others

What the payments were for

  • Food & beverage$679100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$679 in reported general payments places this provider in the 35th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$399,431
Medicare patients
661
Services billed
2,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BesivanceBesifloxacin Hcl98$21,327
Lotemax SmLoteprednol Etabonate54$15,304
ProlensaBromfenac Sodium39$13,295
LumiganBimatoprost18$8,180
EysuvisLoteprednol Etabonate14$7,011
RocklatanNetarsudil Mesylat/Latanoprost12$4,170
Bromfenac Sodium14$3,565
Tobramycin-DexamethasoneTobramycin/Dexamethasone44$3,087
Brimonidine Tartrate34$2,428
Prednisolone Acetate44$1,421
Timolol Maleate81$1,208
Latanoprost119$1,093
Azelastine Hcl14$663
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat23$370
ErythromycinErythromycin Base32$299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Lotemax Sm, Prolensa$25$49,925191 claims
Kala Pharmaceuticals, Inc.Eysuvis$38$7,01114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Oxnard

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →